Developing next-generation immunotherapeutic viruses to help patients defeat cancer
At the cutting edge of oncolytic viral immunotherapy
Vaxalto’s innovative, multimodal platform harnesses the power of direct tumor destruction and immune system activation for complete tumor eradication. Our breakthrough technology boasts high efficacy and safety and has yielded unprecedented pre-clinical results.
APMV
oncolytic virus
Powerful
immunomodulator
System-wide
tumor eradication
ABOUT US
On a mission to reimagine cancer treatment
Vaxalto Biotherapeutics is a pre-clinical stage biotechnology company focused on developing and commercializing viral immunotherapies. Our proprietary, multimodal virus platform has been engineered to potently stimulate the immune system against cancer, providing uniquely safe and effective treatment. Scientific leadership consists of experts in virology, immunology, vaccines, and cancer biology from the Icahn School of Medicine at Mount Sinai in New York.
CONTACT US
Get involved in the future of medicine
We are seeking partners to advance our programs into clinical testing and set a new standard for safe and effective cancer treatments.
CONTACT US
Get involved in the future of medicine
We are seeking partners to advance our programs into clinical testing and set a new standard for safe and effective cancer treatments.